Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)

Historic Preferred Stock Liabilities for Immuneering (IMRX) over the last 2 years, with Q2 2021 value amounting to $82.9 million.

  • Immuneering's Preferred Stock Liabilities changed N/A to $82.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $82.9 million, marking a year-over-year change of. This contributed to the annual value of $58.1 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that Immuneering reported Preferred Stock Liabilities of $82.9 million as of Q2 2021.
  • Over the past 5 years, Immuneering's Preferred Stock Liabilities peaked at $82.9 million during Q2 2021, and registered a low of $58.1 million during Q4 2020.